Title : Cost-effectiveness of targeted therapy with cetuximab in patients with K-ras wild-type colorectal cancer presenting with initially unresectable metastases limited to the liver in a German setting.

Pub. Date : 2011 Apr

PMID : 21635994






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 RESULTS: For the metastatic colorectal cancer LLD population with K-ras wild-type genotype, mean overall survival estimates were 37.7 months for first-line treatment with cetuximab plus FOLFIRI (irinotecan, leucovorin, fluorouracil) and 30.4 months for bevacizumab plus FOLFOX (oxaliplatin, leucovorin, fluorouracil). Oxaliplatin KRAS proto-oncogene, GTPase Homo sapiens